Sagimet Biosciences Inc. priced a new equity offering on April 27, 2026 that will raise roughly $175 million. The company is selling 29,166,700 shares of Series A common stock at $6.00 per share, with gross proceeds expected to be about $175 million before underwriting discounts and commissions. Net proceeds are estimated at $163.9 million to $164.5 million after fees.
The capital will be directed toward several key clinical milestones: a Phase 3 trial of denifanstat in moderate‑to‑severe acne in the United States, support for the TVB‑3567 program through Phase 2 topline results, advancement of a topical formulation of its fatty‑acid‑synthase (FASN) inhibitor to IND submission, and general corporate purposes such as working capital and operating expenses. These uses align with Sagimet’s strategy to prioritize its dermatology franchise while pausing further development of its MASH program unless non‑dilutive funding is secured.
Prior to the offering, Sagimet’s cash balance stood at approximately $104.5 million as of March 31, 2026. The infusion of capital is expected to extend the company’s runway through 2028, providing a financial cushion to reach the planned clinical milestones without additional debt. The net proceeds will also help mitigate dilution risk by reducing the need for future equity raises.
Management emphasized the strategic focus behind the offering. CEO David Happel said, "Building on the recent successful Phase 3 clinical trial in China of our lead molecule denifanstat in moderate to severe acne, we have taken the strategic decision to advance denifanstat in acne for the U.S., starting with a Phase 3 clinical trial expected to begin in the second half of 2026." CFO Thierry Chauche added, "We are prioritizing our dermatology franchise in our capital allocation, and we plan to pursue non‑dilutive funding options for our MASH program." Earlier, Happel noted that the clearance of the TVB‑3567 IND marks a significant milestone as the company expands its dermatology pipeline.
The announcement triggered a sharp market reaction. Shares surged over 45% in morning trading and rose about 30% later in the day. Investors were driven by the prospect of a U.S. Phase 3 trial for denifanstat, the company’s clear pivot toward dermatology, and the perceived value of a first‑in‑class oral acne therapy in a $11 billion global market. The equity offering, while dilutive, was viewed as a necessary step to fund these high‑potential programs.
The equity raise strengthens Sagimet’s balance sheet and positions the company to execute its clinical strategy. While shareholders will experience dilution, the capital infusion supports a focused dermatology pipeline, potentially accelerating regulatory progress and market entry. The move also signals management’s confidence in the commercial prospects of denifanstat and TVB‑3567, and it underscores a broader shift toward non‑dilutive funding for the MASH program.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.